Mosaic Biosciences Strengthens Its Position in Drug Discovery and Development
Wednesday, April 03, 2024
Mosaic Biosciences, a prominent player in the field of drug discovery, has announced the appointment of two distinguished leaders to its team: Dr. Malavi Madireddi as Senior Vice President of Drug Discovery and Dr. Scott Glaser as Senior Vice President of Biologics Discovery. These appointments signify a significant advancement for the company as it expands its capabilities to meet the increasing demand for its comprehensive drug discovery services.
Eric Furfine, co-CEO & CSO of Mosaic Biosciences, expressed excitement about the new additions, stating, "Our dedication to delivering unparalleled therapeutic discovery is reinforced by the inclusion of these two outstanding biotech leaders. Malavi's profound understanding of biological complexities and Scott's strategic acumen in protein therapeutic discovery enhance the value we offer to our partners."
Prior to joining Mosaic Biosciences, Dr. Malavi Madireddi brought over 25 years of experience leading successful small molecule and biologic drug discovery teams across various therapeutic areas. At Bristol Myers Squibb (BMS), she served as Head of Innovative Collaborations, leveraging her expertise to drive strategic scientific collaborations. Dr. Madireddi's extensive background includes leadership roles at JDRF-International and significant contributions to autoimmune and metabolic disease research at BMS.
Dr. Malavi expressed her enthusiasm about joining Mosaic Biosciences, stating, "I am eager to utilize my expertise in drug discovery and clinical development to position Mosaic Biosciences as the preferred partner for innovative protein therapeutics. With the evolving landscape of R&D resources, Mosaic Biosciences stands uniquely positioned to redefine collaborative drug discovery without compromising quality."
Dr. Scott Glaser brings over 25 years of biopharma experience to Mosaic Biosciences, having led numerous successful discovery programs and contributed to significant advancements in protein technologies. His prior roles include Director of Antibody Therapeutics at The Genomics Institute of the Novartis Research Foundation (GNF) and leadership positions at Pfizer and Biogen Idec.
Commenting on his new role, Dr. Glaser said, "Mosaic Biosciences is at the forefront of technical innovation and partner support in the discovery of next-generation protein therapeutics. I am excited to collaborate with our talented team and world-class clients."
These strategic leadership appointments underscore Mosaic Biosciences' commitment to innovation and excellence in drug discovery, positioning the company as a leader in the field.
Source: businesswire.com
